| Literature DB >> 35789796 |
Zhao-Ming Chen1, Xiao-Yun Yang1,2, Zheng-Tu Li1, Wei-Jie Guan1,3, Ye Qiu4, Shao-Qiang Li1, Yang-Qing Zhan1, Zi-Ying Lei5, Jing Liu4, Jian-Quan Zhang6, Zhong-Fang Wang1,2, Feng Ye1.
Abstract
Background: Although anti-IFN-γ autoantibodies predispose patients to Talaromyces marneffei infection, whether this is mediated by T cell attenuation remains elusive.Entities:
Keywords: T lymphocyte; Talaromyces marneffei; anti-interferon-γ autoantibody; signal transducer and activator of transcription 1; signal transducer and activator of transcription 3
Year: 2022 PMID: 35789796 PMCID: PMC9250332 DOI: 10.2147/IDR.S364388
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Characteristics of the 16 Patients with T. marneffei Infections and 12 Healthy People During the First Visit
| Variable | Anti-IFN-γ autoAb-Positive | Anti-IFN-γ autoAb-Negative | Healthy Control | |
|---|---|---|---|---|
| (N=11) | (N=5) | (N=12) | ||
| Age, years | 53.0 (35.0, 58.0) | 54.5 (29.0, 63.8) | 37.0 (30.5, 43.8) | 0.126 |
| Male sex, no. (%) | 6 (54.5%) | 3 (60.0%) | 8 (66.7%) | 1.000 |
| Anti-IFN-γ antibody titers (ng/mL) | 1316.2 | 332.4 | 300.5 | <0.001 |
| Skin | 3 (27.3%) | 1 (20.0%) | - | - |
| Lymph node | 7 (63.6%) | 2 (40.0%) | - | - |
| Liver | 2 (9.1%) | 1 (5.0%) | - | - |
| Spleen | 2 (9.1%) | 0 | - | - |
| Bone | 4 (36.4%) | 0 | - | - |
| Pleural effusion | 6 (54.5%) | 0 | - | - |
| In-hospital mortality, no. (%) | 3 (27.3%) | 0 | - | - |
| Unsatisfactory therapeutic effect, no. (%) | 9 (81.8%) | 1 (20.0%) | - | - |
| White-cell count (*109 cells/L) | 15.1 (8.3, 17.3) | 7.2 (4.5, 11.1) | - | - |
| Neutrophil (*109/L) | 10.8 (6.2, 12.1) | 5.1 (3.2, 9.5) | - | - |
| ESR (mm/h) | 99.0 (76.5101.3) | 29.0 (2.50, 67.0) | - | - |
| C-reactive protein (mg/dL) | 43.2 (13.4,72.5) | 5.7 (3.3, 33.5) | - | - |
| PCT>0.05 ng/mL, no. (%) | 9 (81.8%) | 1 (20.0%) | - | - |
| CD3+ T cell count (cells/µL) | 1340.5 (1047.8, 1558.3) | 452.0 (106.81131.00) | - | - |
| CD4+ T cell count (cells/µL) | 701.0 (321.5, 851.8) | 206.5 (24.3, 510.3) | - | - |
| CD8+ T cell count (cells/µL) | 595.5 (316.8, 1018.8) | 191.0 (64.8, 530.3) | - | - |
Notes: P value: comparison of anti-IFN-γ autoAb-positive and anti-IFN-γ autoAb-negative cases.
Abbreviations: ESR, erythrocyte sedimentation rate; PCT, procalcitonin.
Anti-IFN-γ autoAb Titer for Each Participant
| Anti-IFN-γ autoAb Titer (ng/mL) | Healthy people | Anti-IFN-γ autoAb Titer (ng/mL) | |
|---|---|---|---|
| 3433.5 | 348.0 | ||
| 3704.0 | 346.2 | ||
| 2308.7 | 199.3 | ||
| 1310.8 | 326.1 | ||
| 1316.2 | 284.1 | ||
| 921.5 | 307.0 | ||
| 1461.5 | 293.9 | ||
| 3125.5 | 279.7 | ||
| 931.1 | 345.3 | ||
| 909.1 | 314.0 | ||
| 851.2 | 252.0 | ||
| 359.8 | 275.5 | ||
| 371.0 | |||
| 349.3 | |||
| 412.1 | |||
| 207.8 |
Abbreviations: TM, T. marneffei-infected patients; HC, healthy controls.
Figure 2The percentage of CD8+ T cells secreting IFN-γ+ and TNF-α+ among PBMCs from the high-titer autoantibody group, medium-titer autoantibody group and normal serum group. (A-C) show healthy control A, healthy control B and healthy control C, respectively. (D-F) show the correlation between the percentage of CD8+ T cells secreting IFN-γ+ and TNF-α+ in PBMCs and the anti-IFN-γ autoAb titer in 3 healthy controls.
Figure 1The percentage of CD8+ T cells secreting IFN-γ+ TNF-α+ in PBMCs of 3 healthy subjects at Day 10 following in vitro stimulation with M158−66 peptide. (A-C) show healthy control A, healthy control B and healthy control C, respectively. HC1-HC12 represent the serum from 12 healthy controls; TM1-TM10 represent the serum from 10 anti-IFN-γ autoAb-positive patients; NC represents the negative control.
Figure 3The percentage of CD4+ T cells secreting IFN-γ in PBMCs of 5 patients at Day 10 following in vitro stimulation with heat-killed T. marneffei. (A) presents flow cytometry plots (TM2, TM5, TM11, TM12, and TM13 represent PBMCs from 5 patients; P1-P3 represent serum from 3 anti-IFN-γ autoAb-positive patients (TM1, TM2, TM3); HC represents serum from 1 healthy control; NC represents the negative control. (B) shows the significant difference of the percentage of IFN-γ+ CD4+ T cells between the anti-IFN-γ autoAb-positive serum and normal serum groups. (C) and (D) shows no significant difference of the percentage of IFN-γ+ CD4+ T cells between anti-IFN-γ autoAb-positive and negative patients with either high titer IFN-γ autoantibody serum or HC serum culture.
Figure 4Cell supernatant cytokine levels in PBMCs of 5 patients at Day 10 following in vitro stimulation with heat-killed T. marneffei. * P < 0.05, *** P < 0.001, and **** P < 0.0001.
Figure 5Expression of STAT1/STAT3 phosphorylation protein in patients with talaromycosis and healthy controls. (A) Upper bands represent the results of STAT1/STAT3 phosphorylation immunoblotting. Low P1, Low P2 and Low P3 represent 3 anti-IFN-γ autoAb-positive patients; HC 1, HC 2 and HC 3 represent 3 healthy controls; High P1, High P2 and High P3 represent 3 anti-IFN-γ autoAb-negative patients. (B) and (F) present the comparison of STAT1 and STAT3 phosphorylated protein expression between the IFN-γ- or CD3/CD28-stimulated group and the negative control group. (C-E), (G-I) present the differences in STAT1 and STAT3 phosphorylated protein expression after IFN-γ or CD3/CD28 stimulation among anti-IFN-γ autoAb-positive patients, anti-IFN-γ autoAb-negative patients and healthy controls.